🇺🇸

US SEC Filing Intelligence

· daily

US Merger & Acquisition SEC Filings — July 13, 2026

Today's M&A digest is dominated by SPAC activity, with 6 of 11 filings involving blank-check companies. The most significant development is the termination of SC II Acquisition Corp.'s LOI with a payments technology target, a high-materiality negative signal that increases the risk of liquidation. In contrast, Tavia Acquisition Corp. announced a non-binding LOI with Vita Inclinata at a $450M pre-money valuation, providing a clear catalyst for a Q4 2026 de-SPAC. The largest transaction by value is Edgewise Therapeutics' $1.55B upfront sale of its muscular dystrophy business to Servier, a transformative deal that fully funds its cardiovascular pipeline through potential approval. Esperion Therapeutics' acquisition by ArchiMed-backed Essence Parent Inc. includes a Contingent Value Rights (CVR) agreement tied to $300M+ in annual net sales milestones, offering a potential upside kicker for former shareholders. Period-over-period data is limited across these filings, but the pro forma financials from Franklin Street Properties show a $1.1M loss on debt extinguishment from a property sale, while Plum Acquisition Corp. III's pro forma balance sheet reveals a $30M inventory adjustment from a crushed aggregate acquisition. The overall theme is a bifurcated SPAC market: some sponsors are securing extensions and targets, while others are failing to close deals, increasing the risk of liquidations.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 13, 2026

Overnight SEC filings from July 12-13, 2026, reveal a market dominated by corporate actions, regulatory shifts, and capital structure changes, with several high-conviction signals for active investors. The most significant development is the forced delisting of Bowen Acquisition Corp (BOWN) from Nasdaq, a stark reminder of SPAC mortality risk. In the financial sector, Patriot National Bancorp's removal of its 'troubled condition' status marks a major turnaround, while XAI Octagon Floating Rate & Alternative Income Trust is embroiled in a proxy fight following severe underperformance. Capital markets are active, with Public Storage issuing $900M in debt to fund an acquisition and Research Alliance Corp IV launching a $75M SPAC IPO. On the earnings front, Onar Holding Corp reported a 39% revenue surge but with deteriorating margins and a precarious cash position, while Royale Energy narrowed its net loss by 42% despite a 14% revenue decline. Insider activity is notable at SharkNinja, where a waiver was granted for a chairman's share sale, and at Lisata Therapeutics, where a tender offer is set to close. Overall, the filings point to a bifurcated market where disciplined capital allocation and regulatory clarity are rewarded, while companies with weak balance sheets or governance issues face increasing scrutiny.

11 high priority 39 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — July 12, 2026

This digest covers a single, large civilian contract awarded to Brasfield & Gorrie LLC by the FBI (Department of Justice) for $147.6 million in commercial construction in Birmingham, AL. The contract is entirely civilian, with no defense exposure, and represents a stable, high-priority federal infrastructure investment. The highest-conviction signal is the firm-fixed-price structure, which provides predictable revenue but also exposes the contractor to execution risk over the three-year performance period. A key watch item is the low initial outlay of only $9.6 million, indicating early-stage execution and potential for significant revenue recognition ahead, but also risk of funding delays under a potential Continuing Resolution.

1 total filings
· daily

New Federal Contractors — July 12, 2026

This digest covers a single, large civilian contract awarded to Brasfield & Gorrie LLC by the FBI (Department of Justice) for $147.6 million in commercial construction. The contract is a firm-fixed-price award with full and open competition, signaling a competitive win in the stable federal construction sector. With only $9.6 million outlaid so far, the contract is in early execution stages, offering predictable but back-loaded revenue recognition. The key risk is execution pace and potential budget delays under a continuing resolution, though FBI infrastructure spending is typically sustained. The highest-conviction signal is the neutral, competitive nature of the award, which provides no clear moat but reduces protest risk.

1 total filings
· daily

Significant Contract Modifications ($10M+) — July 12, 2026

This digest covers a single significant contract modification from July 12, 2026, totaling $147.6 million, entirely civilian (Department of Justice/FBI). The award to Brasfield & Gorrie LLC for commercial construction in Birmingham, AL, is a firm-fixed-price contract with full and open competition, signaling a competitive win in stable federal security infrastructure. The neutral signal (strength 5/10) reflects predictable revenue but early-stage execution risk, with only $9.6 million outlaid. Key watch items include future outlay pace and potential modifications to increase total value.

1 total filings
· daily

Contract Deobligations Alert — July 12, 2026

This digest covers a single $147.6 million contract deobligation from the FBI (Department of Justice) to Brasfield & Gorrie LLC for commercial construction in Birmingham, AL. The contract is entirely civilian (0% defense-related) and represents a competitive, firm-fixed-price award with a medium signal strength of 5/10. The key investment story is a stable, predictable revenue stream for Brasfield & Gorrie over three years, but with only $9.6 million outlaid so far, execution pace and future funding releases are critical to monitor. The dominant theme is sustained federal infrastructure spending for security agencies, though the contract's size relative to Brasfield & Gorrie's overall portfolio is likely modest given the company's large-scale construction focus.

1 total filings
· daily

Contract Option Exercises — July 12, 2026

This digest covers a single $147.6 million contract option exercise from the Department of Justice (FBI) to Brasfield & Gorrie LLC for commercial construction in Birmingham, AL. The contract is entirely civilian (0% defense-related), with a neutral signal strength of 5/10 and a materiality score of 6/10. The highest-conviction signal is the early-stage revenue recognition—only $9.6 million outlaid so far—suggesting most of the $147.6 million will be recognized over the next three years. A key risk is the firm-fixed-price structure, which transfers cost overrun risk to Brasfield & Gorrie, though the stable FBI funding profile mitigates cancellation risk. No bullish or bearish signals were identified, reflecting a routine, competitive award with no set-aside or sole-source dynamics.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 12, 2026

This digest covers a single $147.6 million civilian contract awarded by the FBI to Brasfield & Gorrie LLC for commercial construction in Birmingham, AL, with a performance period through May 2028. The contract is entirely civilian, reflecting stable DOJ/FBI security infrastructure spending, and carries a neutral signal with medium execution risk due to its firm-fixed-price structure and early-stage outlay of only $9.6 million. The highest-conviction signal is the predictable revenue stream over three years, but the key risk is the early-stage execution and potential delays in funding releases. Investors should monitor future outlay amounts and any modifications that could expand total contract value.

1 total filings
· daily

High-Value Federal Grants ($5M+) — July 12, 2026

Today's digest covers a single, large civilian contract: a $147.6 million firm-fixed-price award from the FBI to Brasfield & Gorrie LLC for commercial construction in Birmingham, AL. The contract is 100% civilian (DOJ/FBI), with zero defense exposure, and represents a stable, high-priority security infrastructure project. The highest-conviction signal is neutral: the firm-fixed-price structure provides predictable revenue, but only $9.6 million has been outlaid, indicating early-stage execution and potential revenue recognition risk over the next few years. Key watch items include monitoring future outlay amounts and any modifications or option exercises that could increase total contract value.

1 total filings
· daily

General Federal Contracts — July 12, 2026

Over this single-day period, the digest captures a solitary $147.6 million civilian contract awarded to Brasfield & Gorrie LLC by the FBI (Department of Justice) for commercial construction in Birmingham, AL. This is entirely non-defense, representing zero defense exposure, and carries a neutral signal strength of 5/10. The highest-conviction signal is the contract's firm-fixed-price structure, which provides Brasfield & Gorrie with predictable revenue over the three-year performance period (through May 2028), but the early-stage execution—with only $9.6 million outlaid so far—introduces material revenue recognition risk. The dominant theme is stable, non-tech civilian infrastructure, which offers low growth visibility but low cancellation risk given the FBI's high-priority status.

1 total filings
· daily

Biotech Small-Cap Approvals — July 11, 2026

The July 11, 2026 approval stream is dominated by 5 biosimilar/fallback approvals and 1 NME, presenting a mixed but actionable picture for biotech investors. The standout event is VERA THERAPEUTICS INC.'s NME approval for ATACIEPT-VYMJ (TRUTAKNA) under Priority Review, a clear bullish signal for the sponsor given the high approval bar and expedited review. The remaining 5 approvals are neutral biosimilar entries for established molecules (DESOGESTREL, DIMETHYL SULFOXIDE, MORPHINE SULFATE, VARENICLINE TARTRATE, NITROGLYCERIN) from small-cap sponsors like ANNORA PHARMA, STIRA, QUAGEN, SOMERSET THERAPS LLC, and PADAGIS ISRAEL, which lack disclosed commercial data and face intense generic competition. The key risk is the lack of differentiation and pricing power for these biosimilars, while the primary opportunity is VERA's NME launch trajectory and potential market creation. No dominant therapeutic area theme emerges, but the concentration of biosimilar approvals signals ongoing commoditization in legacy drug markets.

6 total filings
· daily

NME Blockbuster Approvals — July 11, 2026

This single-approval period features one NME approval—ATACIEPT-VYMJ (TRUTAKNA) from VERA THERAPEUTICS INC.—granted under Priority Review. No biosimilars or label expansions were approved, making this a focused, high-conviction event for VERA. The dominant theme is a novel therapeutic entry with regulatory priority, signaling strong unmet need. The highest-conviction signal is the NME approval itself, which provides VERA with 5-year NCE data exclusivity and a potential commercial catalyst. Key risk is the lack of disclosed commercial data (peak sales, pricing, market position), which limits near-term revenue visibility for investors.

1 total filings
· daily

New Drug Approvals (Original) — July 11, 2026

During the period of July 11, 2026, the FDA approved 6 new drug applications, comprising 0 NMEs, 0 biosimilars, 0 label expansions, and 6 'Other' approvals (primarily biosimilar-type fallback approvals). The most significant event is the NME approval of ATACIEPT-VYMJ (TRUTAKNA) by VERA THERAPEUTICS INC., which received Priority Review and represents the sole bullish signal. The remaining five approvals are neutral biosimilar or generic-type entries for DESOGESTREL (ANNORA PHARMA), DIMETHYL SULFOXIDE (STIRA), MORPHINE SULFATE (QUAGEN), VARENICLINE TARTRATE (SOMERSET THERAPS LLC), and NITROGLYCERIN (PADAGIS ISRAEL). No dominant therapeutic area theme emerged, as the approvals span contraception, pain, smoking cessation, and cardiovascular indications. Key watch items include the commercial launch trajectory of TRUTAKNA and potential competitive dynamics in the smoking cessation market from the VARENICLINE TARTRATE approval.

6 total filings
· daily

DHS Homeland Security Contracts — July 11, 2026

The single contract analyzed, a $98.7 million firm-fixed-price delivery order from the Department of Homeland Security (DHS) to Smiths Detection Inc., underscores a civilian security screening theme with zero defense exposure. The award is non-competitive, suggesting Smiths Detection holds a proprietary or incumbent position for TSA explosive detection systems, providing revenue visibility through August 2027. However, only $42.4 million has been outlayed, leaving $56.3 million in future obligations subject to budget execution risk under a potential Continuing Resolution. The neutral signal strength (5/10) reflects balanced risk-reward: predictable fixed-price revenue offset by medium pricing risk and lack of competitive validation. Key watch items include TSA's future solicitation strategy and Smiths Detection's cost performance on this fixed-price contract.

1 total filings
· daily

New Federal Contractors — July 11, 2026

The single contract recorded for July 11, 2026, is a $98.7 million sole-source delivery order from the Transportation Security Administration (TSA) to Smiths Detection Inc., a foreign-owned manufacturer of explosive detection systems. This civilian award accounts for 100% of the period's total obligation, with no defense-related contracts in the stream. The highest-conviction signal is Smiths Detection's non-competitive position, suggesting a durable incumbent relationship with TSA, though only $42.4 million has been outlayed, leaving $56.3 million in future obligations at risk under a continuing resolution. Key risks include fixed-price execution pressure on margins and the lack of competitive validation for pricing. The neutral signal strength (5/10) reflects a stable but unexciting single-award profile.

1 total filings
· daily

Significant Contract Modifications ($10M+) — July 11, 2026

This digest covers a single $98.7 million civilian contract modification awarded to Smiths Detection Inc. by the Department of Homeland Security (TSA) for medium-speed explosive detection systems. The contract is a firm-fixed-price delivery order, awarded non-competitively, signaling an incumbent or sole-source position. With $42.4 million already outlayed and the remainder due through August 2027, the award provides multi-year revenue visibility but carries medium pricing risk. The key signal is neutral, reflecting a stable, non-competitive renewal in a mature security screening market. Investors should watch for future TSA competitive solicitations that could challenge Smiths Detection's incumbent position.

1 total filings
· daily

Contract Deobligations Alert — July 11, 2026

This digest covers a single $98.7 million civilian contract deobligation from the Department of Homeland Security to Smiths Detection Inc., a foreign-owned manufacturer of explosive detection systems. The award is a firm-fixed-price delivery order from the Transportation Security Administration for medium-speed explosive detection systems, with $42.4 million already outlayed and $56.3 million in potential future obligations through August 2027. The contract was awarded non-competitively, suggesting an incumbent or sole-source position, which is a moderately bullish signal for Smiths Detection's revenue visibility. However, the neutral signal strength (5/10) and medium pricing risk reflect the fixed-price nature of the contract, which could compress margins if costs rise. Key watch items include future TSA solicitations for competitive dynamics and Smiths Detection's cost performance on this fixed-price contract.

1 total filings
· daily

Contract Option Exercises — July 11, 2026

The single contract option exercise analyzed for July 11, 2026, totals $98.7 million, entirely civilian (Department of Homeland Security/TSA), with no defense-related awards. The sole award to Smiths Detection Inc. for medium-speed explosive detection systems reflects a non-competitive, sole-source follow-on arrangement, signaling an entrenched incumbent position in TSA security screening. The highest-conviction signal is the neutral-to-bullish moat implied by the lack of competition, though the fixed-price structure introduces execution risk. A key watch item is the $56.3 million in un-outlayed funds through August 2027, which could be vulnerable to budget shifts or contract protests.

1 total filings
· daily

High-Value Federal Grants ($5M+) — July 11, 2026

The single high-value federal grant analyzed for July 11, 2026, totals $98.7 million, entirely civilian (Department of Homeland Security/TSA), with no defense-related awards. The dominant theme is continued investment in aviation security screening technology, specifically explosive detection systems. The highest-conviction signal is Smiths Detection's sole-source, firm-fixed-price delivery order, which suggests an entrenched incumbent position but carries medium execution risk due to fixed-price cost overrun exposure. A key watch item is the $56.3 million in unfunded future obligations through August 2027, which could be vulnerable under a potential Continuing Resolution or budget reallocation.

1 total filings
· daily

General Federal Contracts — July 11, 2026

This single-contract digest covers a $98.7 million civilian award from the Department of Homeland Security (TSA) to SMITHS DETECTION INC. for medium-speed explosive detection systems, with zero defense-related contracts. The dominant theme is continued investment in aviation security screening technology, driven by TSA’s non-competitive procurement from an established incumbent. The highest-conviction signal is the sole-source nature of the award, which underscores SMITHS DETECTION’s entrenched position but also limits competitive visibility. Key risks include fixed-price execution pressure on margins and the $56.3 million in unfunded future obligations that depend on budget continuity and TSA priorities.

1 total filings